Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
about
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasWW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancerPhosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell linesCharacterisation of HER heterodimers in breast cancer using in situ proximity ligation assayEssential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patientsOutcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labellingNew targets for therapy in breast cancer: small molecule tyrosine kinase inhibitorsCardiac toxicity of trastuzumab in elderly patients with breast cancerRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsNatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancerTargeting of erbB3 receptor to overcome resistance in cancer treatmentQuantification of HER family receptors in breast cancerRegulation of ERBB3/HER3 signaling in cancerHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerT cell receptor-like recognition of tumor in vivo by synthetic antibody fragmentAffibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imagingEstrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradationLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meMembranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cellsEnhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cellsAkt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis.Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.Differential Shannon entropy and differential coefficient of variation: alternatives and augmentations to differential expression in the search for disease-related genes.The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.
P2860
Q21144348-1956486F-1716-433A-A971-FE251F275276Q24309041-A2AF5D78-5035-47C4-BE8D-ECA8FB400C1BQ24318725-D6F0551B-246B-4877-B043-6790201C4FD0Q24337937-BB709C98-9D22-46F4-B2DC-7801C3F84C24Q24537669-ADF0E2E5-F894-4BE1-986D-18F07D4EF006Q24645597-E36A43F6-BBFE-47CF-BA30-7CA30CB6716AQ24794988-7DCA2DDD-22FD-4350-BA6C-7A4CFA8CE941Q24806486-234A9E87-2A5A-4AC0-807F-F4DC55C837FCQ26741182-2C64ECBF-AE6C-46E8-8FB5-10BE2EFC292EQ26750428-14E8939B-3027-466C-BB00-A5848A4F0F9CQ26782856-001DD472-45E6-434A-B472-49C0A7120447Q26864668-C9412708-2989-414D-B9B8-0392E2CF123CQ27015506-DD1646B0-23FE-48DD-90EA-0E16558A5B96Q27024334-E5D75627-A8F6-40FA-8524-6C4CE94F2C0FQ27025863-13EB4A82-42C7-498C-B35C-A8CB964EB113Q27322455-5880D860-B085-41FE-B7D6-E3E2A2C127ECQ27333491-2EC1ED16-664F-42C8-9157-AC90CF50E182Q27851630-33CE1968-A867-4C8F-B3A7-8013B7CF9859Q27853060-9E59F65B-1B0D-47A7-9C46-2AC81BC84734Q28067145-BCCAB45D-5D48-43B2-8B47-9877E19B26B6Q28084982-EED4A2D8-105D-4927-9824-EE537FD80113Q28511737-3BA8AB9E-93C6-4D53-B405-BDD7EF0B8B13Q30366990-B3314AAB-8C05-4FF2-AD9A-79C0254EDF50Q30376023-663EF016-FD87-4D59-A503-4E42E99A22F2Q30430971-2447F988-3C50-41BD-B1AF-FE74CD4AD18BQ30997919-31187E59-DB97-438C-B168-1278518FB515Q31129446-E9896108-19D4-43CC-BAA7-90EAC89E081FQ31134061-D400E9D5-8F56-49B3-9CE6-43B9137B1FEBQ33279445-31CEF05A-E688-4B30-B0AB-1D657B61BF00Q33514127-F823F69E-02E0-4907-A861-38F41B88F22CQ33538332-06C61657-C2B7-4B56-8F22-251BD4CD320AQ33614071-EE86CC33-5E61-46E3-848A-AEE81BF37C09Q33870552-B6E78DBA-1618-4DFD-99DF-EAF8A9D78AB3Q33917957-7625605B-C460-4070-BF47-0B15449D9023Q33995239-EFF3D4A2-5C4D-4793-8ECC-C6B097DC889CQ34020239-790F3C88-9931-4B3C-A201-A042974DCD23Q34048265-71EE1D62-0640-4A99-9200-E87594BED394Q34048293-EC219E0A-7C1D-4666-81B5-1ED21D98B02CQ34103963-573C0746-4A80-4238-8AE4-D55926CFC428Q34121278-184C4EC1-2DF0-4E3A-A357-9FB0DF42F3E7
P2860
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@en
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@nl
type
label
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@en
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@nl
prefLabel
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@en
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@nl
P2093
P2860
P356
P1476
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
@en
P2093
Caroline J Witton
John M S Bartlett
Jonathan R Reeves
Timothy G Cooke
P2860
P304
P356
10.1002/PATH.1370
P577
2003-07-01T00:00:00Z